Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin

BACKGROUND: We compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes. METHODS: The present study was a multicenter, random...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jong Ho, Kim, Sang Soo, Baek, Hong Sun, Lee, In Kyu, Chung, Dong Jin, Sohn, Ho Sang, Bae, Hak Yeon, Kim, Mi Kyung, Park, Jeong Hyun, Choi, Young Sik, Kim, Young Il, Hahm, Jong Ryeal, Lee, Chang Won, Jo, Sung Rae, Park, Mi Kyung, Lee, Kwang Jae, Kim, In Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Diabetes Association 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929227/
https://www.ncbi.nlm.nih.gov/pubmed/27098505
http://dx.doi.org/10.4093/dmj.2016.40.3.230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929227/
https://www.ncbi.nlm.nih.gov/pubmed/27098505
http://dx.doi.org/10.4093/dmj.2016.40.3.230

Ejemplares similares